Free Trial

Scancell (LON:SCLP) Shares Up 29.8% - What's Next?

Scancell logo with Medical background

Scancell Holdings plc (LON:SCLP - Get Free Report)'s share price was up 29.8% during mid-day trading on Monday . The stock traded as high as GBX 11.38 ($0.15) and last traded at GBX 11 ($0.15). Approximately 10,537,342 shares traded hands during trading, an increase of 1,073% from the average daily volume of 897,982 shares. The stock had previously closed at GBX 8.48 ($0.11).

Scancell Trading Up 5.5 %

The business's 50 day simple moving average is GBX 8.58 and its 200 day simple moving average is GBX 10.79. The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01. The company has a market capitalization of £109.27 million, a price-to-earnings ratio of -16.18 and a beta of 0.35.

Scancell (LON:SCLP - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) earnings per share for the quarter. Research analysts anticipate that Scancell Holdings plc will post -2.5361112 EPS for the current year.

Scancell Company Profile

(Get Free Report)

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.

See Also

Should You Invest $1,000 in Scancell Right Now?

Before you consider Scancell, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scancell wasn't on the list.

While Scancell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in May 2025
3 Stocks Offering Rare Generational Buying Opportunities
Make Your Money Work Harder: The Power of Dividend Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines